A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma

NCT01936389 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Exfoliation Syndrome
Ocular Hypertension
Open Angle Glaucoma

Interventions

DRUG: AR-12286

Sponsor

Robert Ritch, MD, LLC.